Synthesis, Antiglycating and Antioxidant activities of Triazolo hexahydroquinazolines

Umasankar Kulandaivelu, Srikanth Challuri, Rajasekhar Alavala Reddy, Gomathi Periyasamy, Shireesha Boyapati


Some 5-aryl-triazolo[4,3-a] hexahydro quinazoline derivatives (4a-4e & 5a-5e) were synthesized and evaluated for their in vitro antiglycation and antioxidant activities. Title compounds were found to have potent antiglycating activity than rutin in the range between 0.096 and 0.300 M.The compounds 4b and 5c were the most active ones among them. The tested compounds had shown potent to moderate antioxidant activity by DPPH assay than BHT except 5e (p-NO2 phenyl derivative). Among all, hydroxyl derivatives (4a-4e) are more potent than the corresponding thiols (5a-5e).


Hexahydroquinazolines; Triazole; Antiglycating agents; Antioxidant agents

Full Text:



Brownlee, M. Lilly Lecture 1993. Glycation and diabetic complications. Diabetes 1994, 43, 836-41.

Peppa, M.; Uribarri, J.; Vlassara, H. Glucose, Advanced Glycation End Products, and Diabetes Complications: What Is New and What Works. Clin. Diabetes 2003, 21, 186-187.

Monnier, V. M. Intervention against the Maillard reaction in vivo. Arch Biochem Biophys 2003, 419, 1-15.

Vasan, S.; Foiles, P.; Founds, H. Therapeutic potential of breakers of advanced glycation end product-protein crosslinks. Arch Biochem Biophys 2003, 419, 89-96.

Hunt, J. V.; Bottoms, M. A.; Mitchinson, M. J. Oxidative alterations in the experimental glycation model of diabetes mellitus are due to protein-glucose adduct oxidation. Some fundamental differences in proposed mechanisms of glucose oxidation and oxidant production. Biochem J 1993, 291 (Pt 2), 529-535.

Ahmed, N. Advanced glycation endproducts--role in pathology of diabetic complications. Diabetes Res Clin Pract 2005, 67, 3-21.

Ahmad, M. S.; Ahmed, N. Antiglycation properties of aged garlic extract: possible role in prevention of diabetic complications. J Nutr 2006, 136, 796S-799S.

Gugliucci, A. Glycation as the glucose link to diabetic complications. J Am Osteopath Assoc 2000, 100, 621-634.

Singh, R.; Barden, A.; Mori, T.; Beilin, L. Advanced glycation end-products: a review. Diabetologia 2001, 44, 129-146.

Alagarsamy, V.; Muthukumar, V.; Pavalarani, N.; Vasanthanathan, P.; Revathi, R.; Synthesis, analgesic and anti-inflammatory activities of some novel 2,3-disubstituted quinazolin-4(3H)-ones. Biol Pharm Bull 2003, 26, 557-559.

Shetha, A.; Wijdan, I. A. Synthesis and characterization of new quinazoline-4(3H)-one Schiff bases. J Chem Pharm Res 2013, 5, 4245.

Patel, N. B.; Patel, V. N.; Patel, H. R.; Shaikh, F. M.; Patel, J. C. Synthesis and microbial studies of (4-oxo-thiazolidinyl) sulfonamides bearing quinazolin-4(3H)ones. Acta Pol Pharm 2010, 67, 267275.

Pati, B.; Banerjee, S. Quinazolines: an illustrated review. J Adv Pharm Edu & Res 2013, 3, 13651.

Rudrapal, M.; De, B. Chemistry and biological importance of heterocyclic Schiff 's bases. Int Res J Pure & App Chem 2013, 3, 232249.

Vagdevi, H. M .; Lokesh, M. R.; Gowdarshivannanavar, B. C. Synthesis and antioxidant activity of 3-substituted Schiff bases of quinazoline-2,4-diones. Int J Chem Tech Res 2012, 4, 15271533.

Abid, O. H.; Ahmed, A. H. Synthesis and characterization of novel quinazoline derivatives via reaction of isatoic anhydride with schiff 's base. Int J App Nat Sci 2013, 2, 11-20.

Krishnan, S. K.; Ganguly, S.; Veerasamy, R.; Jan, B. Synthesis, antiviral and cytotoxic investigation of 2-phenyl-3-substituted quinazolin-4(3H)-ones. Eur Rev Med Pharmacol Sci 2011, 15, 673681.

Saravanan, G.; Pannerselvam, P.; Prakash, C. R. Synthesis, analgesic and anti-inflammatory screening of novel Schiff bases of 3-amino-2-methyl quinazoline 4-(3H)-one. Der Pharmacia Lettre 2010, 2, 216226.

Fan, W. Q.; Katritzky, A. R. 1,2,3-Triazoles. In Comprehensive Heterocycle Chemistry II; Katritzky, A.R.; Rees, C. W.; Scriven, E.F.V.; Eds.; Pergamon Press: New York, NY, USA, 1996; 4, 1126.

Biorn, A. C.; Cocklin, S.; Madani, N.; Si, Z.; Ivanovic, T.; Samanen, J.; Ryk, D. I. V.; Pantophlet, R.; Burton, D. R.; Freire, E.; Sodroski, J.; Chaiken, I. M. Mode of action for linear peptide inhibitors of HIV-1 gp120 interactions. Biochemistry 2004, 43, 19281938.

Whiting, M.; Muldoon, J.; Lin, Y. C.; Silverman, S. M.; Lindstrom, W.; Olson, A. J.; Kolb, H. C.; Finn, M. G.; Sharpless, B. K.; Elder, J. H.; Fokin, V. V. Inhibitors of HIV-1 protease by using in situ click chemistry. Angew. Chem. Int. Ed. 2006, 45, 14351439.

Wang, Z. J.; Gao, Y.; Hou, Y. L.; Zhang, C.; Yu, S. J.; Bian, Q.; Li, Z. M.; Zhao, W. G. Design, synthesis, and fungicidal evaluation of a series of novel 5-methyl-1H-1,2,3-trizole-4-carboxyl amide and ester analogues. Eur. J. Med. Chem. 2014, 86, 8794.

Brockunier, L. L.; Parmee, E. R.; Ok, H. O.; Candelore, M. R.; Cascieri, M. A.; Colwell, L. F.; Eng, L.; Feeney, W. P.; Forrest, M. J.; Hom, G. J.; MacIntyre, D. E.; Tota, L.; Wyvratt, M. J.; Fisher, M. H.; Weber, A. E. Human beta3-adrenergic receptor agonists containing 1,2,3-triazole substituted benzenesulfonamides. Bioorg. Med. Chem. Lett. 2000, 10, 21112114.

Pande, V.; Ramos, M. J. Structural basis for the GSK-3beta binding affinity and selectivity against CDK-2 of 1-(4-aminofurazan-3yl)-5-dialkylaminomethyl-1H-[1,2,3]triazole-4-carboxylic acid derivatives. Bioorg. Med. Chem. Lett. 2005, 15, 51295135.

Olesen, P. H.; Srensen, A. R.; Urs, B.; Kurtzhals, P.; Bowler, A. N.; Ehrbar, U.; Hansen, B. F. Synthesis and in vitro characterization of 1-(4-Aminofurazan-3-yl)-5-dialkylamino-methyl-1H- [1,2,3]triazole-4-carboxylic acid derivatives. A new class of selective GSK-3 inhibitors. J. Med. Chem. 2003, 46, 33333341.

Krasinski, A.; Radic, Z.; Manetsch, R.; Raushel, J.; Taylor, P.; Sharpless, B. K.; Kolb, H. C. In situ selection of lead compounds by click chemistry: Target-guided optimization of aceylcholinesterase inhibitors. J. Am. Chem. Soc. 2005, 127, 66866692.

Mocharla, V. P.; Colasson, B.; Lee, L. V.; Roeper, S.; Sharpless, B. K.; Wong, C. H.; Kolb, H. C. In situ click chemistry: Enzyme-generated inhibitors of carbonic anhydrase II. Angew. Chem. Int. Ed. 2005, 44, 116120.

Degenhardt, T. P.; Alderson, N. L.; Arrington, D. D.; Beattie, R. J.; Basgen, J. M.; Steffes, M. W.; Thorpe, S. R.; Baynes, J. W. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 2002, 61, 939-950.

Forbes, J. M.; Soulis, T.; Thallas, V.; Panagiotopoulos, S.; Long, D. M.; Vasan, S.; Wagle, D.; Jerums, G.; Cooper, M. E. Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia 2001, 44, 108-14.

Lehman, T. D.; Ortwerth, B. J. Inhibitors of advanced glycation end product-associated protein cross-linking. Biochim Biophys Acta 2001, 1535, 110-119.

Price, D. L.; Rhett, P. M.; Thorpe, S. R.; Baynes, J. W. Chelating activity of advanced glycation end-product inhibitors. J Biol Chem 2001, 276, 48967-48972.

Nakagawa, T.; Yokozawa, T.; Terasawa, K.; Shu, S.; Juneja, L. R. Protective activity of green tea against free radical- and glucose-mediated protein damage. J Agric Food Chem 2002, 50, 2418-2422.

Braca, A.; Sortino, C.; Politi, M.; Morelli, I.; Mendez, J. Antioxidant activity of flavonoids from Licania licaniaeflora. J Ethnopharmacol 2002, 79, 379-381.

Bors, W.; Saran, M.; Elstner, E. Screening for plant antioxidants. Modern Methods of Plant Analysis-Plant Toxin Analysis-New Series 1992, 13, 277-295.




  • There are currently no refbacks.

Copyright (c)

                              VENSEL PUBLICATIONS@2019

 20, Keelavaithianathapuram, 4th Street, Madurai-625 018 (TN), India